{"id":49639,"date":"2022-10-14T13:02:35","date_gmt":"2022-10-14T11:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/"},"modified":"2022-10-14T13:02:35","modified_gmt":"2022-10-14T11:02:35","slug":"kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/","title":{"rendered":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology\u2019s (ASN) Kidney Week 2022 Annual Meeting, which will take place November 3 \u2013 6, 2022 in Orlando, FL. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation that are not available in the abstract.\n<\/p>\n

<\/a><\/p>\n

\nPoster Presentation Details:<\/b>\n<\/p>\n

\nAbstract Title<\/b>: Zetomipzomib (KZR-616), A First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis: Preliminary Results from the Phase 2 MISSION Study
\n
Session<\/b>: <\/b>Glomerular Diseases: Clinical, Outcomes, Trials – I [PO1303-1]
\n
Date\/Time<\/b>: November 3, 2022 from 10:00 AM – 12:00 PM ET
\n
Presenter<\/b>: Dr. Samir V. Parikh, MD, Associate Professor of Medicine, Division of Nephrology, The Ohio State University Wexner Medical Center\n<\/p>\n

\nAbstract Title<\/b>: Comorbidities and Poor Long-Term Outcomes of Lupus Nephritis in Adult Patients in the United States
\n
Session<\/b>: <\/b>Glomerular Diseases: Lupus and Vasculitis [PO1302-2]
\n
Date\/Time<\/b>: November 4, 2022 from 10:00 AM – 12:00 PM ET
\n
Presenter<\/b>: Dr. Isabelle Ayoub, MD, Associate Professor of Clinical Medicine, Division of Nephrology, The Ohio State University Wexner Medical Center\n<\/p>\n

\nAbstract Title<\/b>: Poor Health-Related Quality of Life in Adult Patients with Lupus Nephritis
\n
Poster Session<\/b>: Glomerular Diseases: Lupus and Vasculitis [PO1302-2]
\n
Date\/Time<\/b>: November 4, 2022 from 10:00 AM – 12:00 PM ET
\n
Presenter<\/b>: Dr. Y. K. O. Teng, MD, PhD, Department of Nephrology, Leiden University Medical Center\n<\/p>\n

\nAbstract Title<\/b>: <\/b>Substantial Economic Burden Associated with the Management of Lupus Nephritis in Adult Patients in the United States
\n
Session<\/b>: Glomerular Diseases: Lupus and Vasculitis [PO1302-2]
\n
Date\/Time<\/b>: November 4, 2022 from 10:00 AM – 12:00 PM ET
\n
Presenter<\/b>: Dr. Brad Rovin, MD, FASN, FACP, Professor of Medicine and Pathology, The Lee A. Hebert Professor of Nephrology, Director, Division of Nephrology, The Ohio State University Wexner Medical Center\n<\/p>\n

\nThe accepted ASN abstracts will be made available today on the congress platform here<\/a>. Following the conference, the presentation materials will be available in the \u201cScientific Publications\u201d section of Kezar Life Science\u2019s website at www.kezarlifesciences.com<\/a>.\n<\/p>\n

\nAbout Zetomipzomib (KZR-616)<\/b>\n<\/p>\n

\nZetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.\n<\/p>\n

\nAbout Kezar Life Sciences<\/b>\n<\/p>\n

\nKezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company\u2019s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Gitanjali Jain
\n
Vice President, Investor Relations and External Affairs
\n
gjain@kezarbio.com<\/a><\/p>\n

Media Contact:<\/b>
Julia Deutsch
\n
Solebury Strategic Communications
\n
jdeutsch@soleburystrat.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology\u2019s (ASN) Kidney Week 2022 Annual Meeting, which will take place November 3 \u2013 6, 2022 in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49639","6":"format-standard","7":"category-industry"},"yoast_head":"\nKezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology\u2019s (ASN) Kidney Week 2022 Annual Meeting, which will take place November 3 \u2013 6, 2022 in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-14T11:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221014005025\/en\/1601691\/21\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting\",\"datePublished\":\"2022-10-14T11:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/\"},\"wordCount\":612,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005025\\\/en\\\/1601691\\\/21\\\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/\",\"name\":\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005025\\\/en\\\/1601691\\\/21\\\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg\",\"datePublished\":\"2022-10-14T11:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005025\\\/en\\\/1601691\\\/21\\\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005025\\\/en\\\/1601691\\\/21\\\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/","og_locale":"en_US","og_type":"article","og_title":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology\u2019s (ASN) Kidney Week 2022 Annual Meeting, which will take place November 3 \u2013 6, 2022 in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-14T11:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221014005025\/en\/1601691\/21\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting","datePublished":"2022-10-14T11:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/"},"wordCount":612,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005025\/en\/1601691\/21\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/","url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/","name":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005025\/en\/1601691\/21\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg","datePublished":"2022-10-14T11:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221014005025\/en\/1601691\/21\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221014005025\/en\/1601691\/21\/Kezar_Life_Sciences_logo_July_2022_%28003%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-society-of-nephrologys-kidney-week-2022-annual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49639"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49639\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}